[go: up one dir, main page]

PT868519E - Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2 - Google Patents

Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2

Info

Publication number
PT868519E
PT868519E PT96940870T PT96940870T PT868519E PT 868519 E PT868519 E PT 868519E PT 96940870 T PT96940870 T PT 96940870T PT 96940870 T PT96940870 T PT 96940870T PT 868519 E PT868519 E PT 868519E
Authority
PT
Portugal
Prior art keywords
aur
polypeptides
diagnosis
treatment
disorders related
Prior art date
Application number
PT96940870T
Other languages
English (en)
Inventor
Gregory D Plowman
Kevin G Mossie
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26678652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT868519(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of PT868519E publication Critical patent/PT868519E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
PT96940870T 1995-12-18 1996-11-25 Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2 PT868519E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US880995P 1995-12-18 1995-12-18
US2394396P 1996-08-14 1996-08-14

Publications (1)

Publication Number Publication Date
PT868519E true PT868519E (pt) 2006-05-31

Family

ID=26678652

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96940870T PT868519E (pt) 1995-12-18 1996-11-25 Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2

Country Status (15)

Country Link
US (2) US5962312A (pt)
EP (2) EP0868519B1 (pt)
JP (1) JP3944241B2 (pt)
KR (1) KR100459052B1 (pt)
AT (1) ATE315654T1 (pt)
AU (1) AU716330B2 (pt)
CA (1) CA2239692C (pt)
DE (1) DE69635740T2 (pt)
DK (1) DK0868519T3 (pt)
ES (1) ES2255715T3 (pt)
IL (1) IL124728A (pt)
NO (1) NO323646B1 (pt)
NZ (1) NZ323795A (pt)
PT (1) PT868519E (pt)
WO (1) WO1997022702A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
WO1999009160A1 (fr) * 1997-08-15 1999-02-25 Chugai Seiyaku Kabushiki Kaisha Proteines de regulation de cycle cellulaire
US5962232A (en) * 1998-01-30 1999-10-05 Incyte Pharmaceuticals, Inc. Protein kinase molecules
EE200200119A (et) 1999-09-21 2003-04-15 Astrazeneca Ab Kinasoliini derivaadid ja nende kasutamine ravimitena
US6352858B1 (en) 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
JP2002236125A (ja) * 2001-02-06 2002-08-23 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体
AU2002322775A1 (en) 2001-07-27 2003-02-17 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
WO2003083096A2 (en) * 2002-03-28 2003-10-09 Qlt Inc. Cancer associated protein kinases and their uses
FR2840905B1 (fr) * 2002-06-12 2006-07-07 Centre Nat Rech Scient Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
US7444273B1 (en) * 2002-06-21 2008-10-28 Takeda San Diego, Inc. Crystallization of aurora/LPL1P-related kinase
EP1578760B1 (en) * 2002-09-11 2014-02-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP4606879B2 (ja) 2002-11-15 2011-01-05 ジェノミック ヘルス, インコーポレイテッド Egfr陽性癌の遺伝子発現プロファイリング
MY136174A (en) 2002-12-24 2008-08-29 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2004211955B2 (en) * 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
JP4568716B2 (ja) * 2003-02-20 2010-10-27 ジェノミック ヘルス, インコーポレイテッド 遺伝子発現を測定するためのイントロンrnaの使用
US20050164218A1 (en) * 2003-05-30 2005-07-28 David Agus Gene expression markers for response to EGFR inhibitor drugs
EP3470535B1 (en) 2003-06-24 2020-04-01 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP3330875B1 (en) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
EP1678327A4 (en) * 2003-10-16 2007-10-10 Genomic Health Inc QRT-PCR TEST SYSTEM FOR GENE EXPRESSION PROFILING
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
DE602004031368D1 (de) * 2003-12-23 2011-03-24 Genomic Health Inc Universelle vervielfältigung von fragmentierter rns
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
CA2566531A1 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006031273A2 (en) * 2004-06-18 2006-03-23 Cytokinetics, Inc. Cellular phenotype
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
AR050948A1 (es) 2004-09-24 2006-12-06 Hoffmann La Roche Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US7930104B2 (en) * 2004-11-05 2011-04-19 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
EP1815014B1 (en) * 2004-11-05 2012-03-21 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
CA2603204A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
US20070082327A1 (en) * 2005-09-09 2007-04-12 Cytokinetics, Inc. A Delaware Corporation Cellular phenotype
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20080020412A1 (en) * 2006-01-03 2008-01-24 Romanowski Michael J Aurora expression constructs
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
JP5279063B2 (ja) * 2007-05-25 2013-09-04 国立大学法人愛媛大学 Hla−a2拘束性抗原ペプチドおよびその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
CA2083401C (en) * 1991-02-22 2003-03-25 Bruce I. Terman Identification of a novel human receptor tyrosine kinase gene
EP0703984A1 (en) * 1993-04-07 1996-04-03 Cancer Research Campaign Technology Limited Methods for screening of substances for therapeutic activity and yeast for use therein
US5830648A (en) * 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging

Also Published As

Publication number Publication date
ES2255715T3 (es) 2006-07-01
WO1997022702A1 (en) 1997-06-26
AU1082697A (en) 1997-07-14
NO982794L (no) 1998-08-18
DK0868519T3 (da) 2006-05-08
EP1655369A1 (en) 2006-05-10
IL124728A0 (en) 1999-01-26
EP0868519A1 (en) 1998-10-07
NO982794D0 (no) 1998-06-17
US5962312A (en) 1999-10-05
KR100459052B1 (ko) 2005-01-15
CA2239692A1 (en) 1997-06-26
EP0868519B1 (en) 2006-01-11
KR20000064437A (ko) 2000-11-06
NZ323795A (en) 2000-01-28
CA2239692C (en) 2008-12-16
AU716330B2 (en) 2000-02-24
IL124728A (en) 2007-06-03
DE69635740D1 (de) 2006-04-06
ATE315654T1 (de) 2006-02-15
JP3944241B2 (ja) 2007-07-11
JP2000502895A (ja) 2000-03-14
US5972676A (en) 1999-10-26
DE69635740T2 (de) 2006-09-14
NO323646B1 (no) 2007-06-18

Similar Documents

Publication Publication Date Title
PT868519E (pt) Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2
WO1999037788A3 (en) Diagnosis and treatment of aur1 and/or aur2 related disorders
EP1361229A3 (en) Use of Tyrosine Kinase (PYK2) to produce antibodies
WO2001055201A8 (en) Nucleic acids, proteins, and antibodies
WO2001054472A8 (en) Nucleic acids, proteins, and antibodies
WO2001055306A3 (en) Nucleic acids, proteins, and antibodies
DK1015477T3 (da) 32 humane sekreterede proteiner
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
WO1997048723A3 (en) Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
DE69734890D1 (de) Rdgb-proteine
WO1996037610A3 (en) Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
WO2001023409A8 (en) 38 human secreted proteins
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
EP1346999A3 (en) Human secreted protein
WO2001055305A3 (en) Nucleic acids, proteins, and antibodies